Literature DB >> 15587392

The effect of sodium butyrate in combination with ATRA on the proliferation/differentiation of SKM-1.

Mei Huang1, Wenli Liu, Chunrui Li, Jinniu Deng, Jianfeng Zhou, Donghua Zhang, Hanying Sun.   

Abstract

To explore the molecular mechanisms of sodium butyrate working on SKM-1 cell proliferation/differentiation and to study its synergistic effect with all-trans retinoic acid (ATRA), SKM-1 cells were grown in the absence or presence of sodium butyrate and/or ATRA. The percentage of viable cells was determined by trypan blue exclusion. Differentiation was determined by nitroblue tetrazolium (NBT) reduction and cell surface adhesion molecules was analyzed by FACS. Cell cycle distribution was examined after DNA staining by propidium iodide. D-type cyclins, cdks and P21 mRNA were studied by reverse transcription-polymerase chain reaction. Our results showed that sodiun butyrate and/or ATRA blocked cells mainly in the G0/G1 phase of the cell cycle. ATRA inhibited the mRNA expression of CDK6, CDK4, cyclinD3 and cyclinD1. Sodium butyrate inhibited the mRNA expression of CDK2, cyclinD2 and cyclinD1. ATRA and sodium butyrate inhibited the mRNA expression of CDK6, CDK4, CDK2, cyclinD1, cyclinD2 and cyclinD3. Both ATRA and/or sodium butyrate stimulated p21 expression at the mRNA levels. Our results suggest that the effect of sodium butyrate on cell proliferation/differentiation might be linked to its ability to induce expression of p21 mRNA and inhibit the cyclin-cdk complexes. Our observations support the notion that the sodium butyrate works synergistically with ATRA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15587392     DOI: 10.1007/bf02861861

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

Review 1.  Chromatin remodeling and leukemia: new therapeutic paradigms.

Authors:  R L Redner; J Wang; J M Liu
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

Review 2.  Coactivator and corepressor complexes in nuclear receptor function.

Authors:  L Xu; C K Glass; M G Rosenfeld
Journal:  Curr Opin Genet Dev       Date:  1999-04       Impact factor: 5.578

Review 3.  Differentiation-inducing agents in the treatment of myelodysplastic syndromes.

Authors:  M Kizaki; H P Koeffler
Journal:  Semin Oncol       Date:  1992-02       Impact factor: 4.929

4.  Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes.

Authors:  C Du; R L Redner; M P Cooke; C Lavau
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

5.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

Review 6.  Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).

Authors:  L R Silverman
Journal:  Oncologist       Date:  2001

7.  Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome.

Authors:  T Nakagawa; S Matozaki; T Murayama; R Nishimura; M Tsutsumi; R Kawaguchi; Y Yokoyama; K Hikiji; T Isobe; K Chihara
Journal:  Br J Haematol       Date:  1993-11       Impact factor: 6.998

8.  Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells.

Authors:  R A Hodin; S Meng; S Archer; R Tang
Journal:  Cell Growth Differ       Date:  1996-05

9.  Inhibition of cyclin-dependent kinases by p21.

Authors:  J W Harper; S J Elledge; K Keyomarsi; B Dynlacht; L H Tsai; P Zhang; S Dobrowolski; C Bai; L Connell-Crowley; E Swindell
Journal:  Mol Biol Cell       Date:  1995-04       Impact factor: 4.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.